{
    "clinical_study": {
        "@rank": "89099", 
        "arm_group": [
            {
                "arm_group_label": "1.Azilsartan Trimethylethanolamine", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of Azilsartan Trimethylethanolamine with 8.75mg,orally"
            }, 
            {
                "arm_group_label": "2.Azilsartan Trimethylethanolamine", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of Azilsartan Trimethylethanolamine with 17.5mg,orally"
            }, 
            {
                "arm_group_label": "3.Azilsartan Trimethylethanolamine", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of Azilsartan Trimethylethanolamine with 35mg,orally"
            }, 
            {
                "arm_group_label": "4.Azilsartan Trimethylethanolamine", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of Azilsartan Trimethylethanolamine with 70mg,orally"
            }, 
            {
                "arm_group_label": "5.Azilsartan Trimethylethanolamine", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of Azilsartan Trimethylethanolamine with 140mg,orally"
            }, 
            {
                "arm_group_label": "6.Azilsartan Trimethylethanolamine", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of Azilsartan Trimethylethanolamine with 210mg,orally"
            }, 
            {
                "arm_group_label": "7.Azilsartan Trimethylethanolamine", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of Azilsartan Trimethylethanolamine with 280mg,orally"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo-matching tablets, orally"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the Pharmacokinetics and safety of Azilsartan\n      Trimethylethanolamine in healthy volunteers"
        }, 
        "brief_title": "A Phase \u2160a Study of Azilsartan Trimethylethanolamine in Healthy Volunteers", 
        "condition": "Health", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males or females\n\n          -  Aged from 18 years to 45 years\n\n          -  Body mass index (BMI) 19 to 25kg/m2\n\n        Exclusion Criteria:\n\n          -  Has a known sensitivity to angiotensin II receptor blocker\uff08ARB\uff09\n\n          -  With evidence of uncontrolled renal, hepatic, central nervous system, respiratory,\n             cardiovascular, or metabolic dysfunction, in the opinion of the investigator or\n             medical monitor\n\n          -  Has known or suspected history of alcoholism or drug abuse or misuse\n\n          -  With a history of laboratory results that show the presence of hepatitis B surface\n             antigen (HBsAg), hepatitis C antibody (HCVAb), or human immunodeficiency virus (HIV)\n\n          -  Pregnant,lactating\uff0cmenstrual\n\n          -  Vegetarian\n\n          -  Postural hypotension\n\n          -  Systolic blood pressure<100mmHg\uff0cor>130mmHg;and/or diastolic blood\n             pressure<70mmHg,or>90mmHg"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01985152", 
            "org_study_id": "HS-AZTP1a"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "1.Azilsartan Trimethylethanolamine", 
                    "2.Azilsartan Trimethylethanolamine", 
                    "3.Azilsartan Trimethylethanolamine", 
                    "4.Azilsartan Trimethylethanolamine", 
                    "5.Azilsartan Trimethylethanolamine", 
                    "6.Azilsartan Trimethylethanolamine", 
                    "7.Azilsartan Trimethylethanolamine"
                ], 
                "intervention_name": "Azilsartan Trimethylethanolamine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 7, 2013", 
        "location": {
            "contact": {
                "last_name": "Jie Hou, Associate Chief Physician", 
                "phone": "86-022-65209939"
            }, 
            "facility": {
                "address": {
                    "city": "Tianjin", 
                    "country": "China"
                }, 
                "name": "TEDA International Cardiovascular Hospital"
            }, 
            "investigator": {
                "last_name": "Jie Hou, Associate Chief Physician", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "8", 
        "official_title": "A Placebo-Controlled, Phase I, Single-center Evaluation of the Single-dose Pharmacokinetics Study of Azilsartan Trimethylethanolamine", 
        "overall_contact": {
            "last_name": "Jie Hou, Associate Chief Physician", 
            "phone": "86-022-65209939"
        }, 
        "overall_official": {
            "affiliation": "TEDA International Cardiovascular Hospital", 
            "last_name": "Jie Hou, Associate Chief Physician", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "To study the Pharmacokinetics of Azilsartan Trimethylethanolamine by assessment of drug concentration through blood sample analysis", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose to 72 hours post-dosee"
            }, 
            {
                "description": "The trial shoud be  terminated \uff0cif more than a third of participants had grade 2 or more than 2 adverse reactions based on Common Terminology Criteria for Adverse Events(CTCAE) Version 4.02", 
                "measure": "Number of participants with adverse reactions", 
                "safety_issue": "Yes", 
                "time_frame": "Pre-dose to 72 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01985152"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Jiangsu Hansoh Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Hansoh Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}